-+ 0.00%
-+ 0.00%
-+ 0.00%
Fu Hong Han Lin (02696): The application for a phase 1 clinical trial of injectable HLX105 for the treatment of advanced/metastatic solid tumors was approved by the China Drug Administration
Share
Listen to the news

Zhitong Finance App News, Fu Hong Han Lin (02696) issued an announcement. Recently, the company's self-developed Phase 1 clinical trial application (IND) for injectable HLX105 (PD-1 antibody fusion protein with IL-2 variant) for the treatment of advanced/metastatic solid tumors was approved by the National Drug Administration (NMPA). HLX105

HLX105 is an antibody fusion protein independently developed by the company that combines the PD-1 antibody with the IL-2 variant. It is intended for the treatment of advanced/metastatic solid tumors. The HLX105 simultaneously blocks the PD-1/PD-L1 pathway and activates the IL-2 pathway. The IL-2 arm of HLX105 retains affinity for IL-2Rα, significantly reducing the ability to bind IL-2Rβ/gamma dimers to human IL2Rα/β/gamma trimers, thereby reducing peripheral toxicity; the PD-1 binding arm can simultaneously block PD-1 and selectively deliver IL-2. IL-2R signals are transmitted to PD-1 positive T cells in the cis-mode to activate tumor-specific T cells and promote their differentiation into more functional effector T cells, thereby exerting specific anti-tumor effects. Preclinical studies have shown that HLX105 has positive anti-tumor efficacy and good safety, and its use in advanced solid tumors is expected to achieve good efficacy and controlled safety.

As of the date of this announcement, no antibody fusion protein products targeting PD-1 and fusing the IL-2 variant have been approved for marketing worldwide.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending